Torrico Tyler, Patel Kajal, Nikolov Nicole, Salam Md Towhid, Padhy Ranjit, Weinstein David
Department of Psychiatry, Kern Medical, Bakersfield, CA, United States.
Ross University School of Medicine, Miramar, FL, United States.
Front Psychiatry. 2024 Jan 10;14:1332999. doi: 10.3389/fpsyt.2023.1332999. eCollection 2023.
Kratom () use in the United States is becoming increasingly popular and its legal status varies widely from state to state. Multiple reports of adverse events associated with kratom use have ranged from liver injury, seizures, psychiatric disturbance, and rarely death.
This study investigated coroner autopsy reports from Kern County in California for the year 2020 which included qualitative data on substances from blood toxicological reports. Of the 214 opioid-associated accidental overdoses reported, 4 subjects (1.9%) had mitragynine (kratom) exposure on the autopsy report and were included in the study. We reported available demographic information and comorbid substance findings from the associated autopsy reports.
All 4 individuals with mitragynine (kratom) toxicology had accidental opioid overdose deaths noted in autopsy reports. Each subject also had toxicology positive for at least one other substance. Fentanyl was found in 3 (75%) of the cases and suspected to be the primary contributor to opioid-related deaths in those cases. However, one fatality was without fentanyl, but instead had tested positive for benzodiazepines, cannabis, and other psychiatric medications.
The findings of this brief report provide insight into the role that mitragynine (kratom) may have in modulating risk of opioid-related deaths. The combined use of kratom with opioids such as fentanyl appears most likely to increase the risk of a fatal overdose, but it may also occur with other medications such as benzodiazepines and psychiatric medications. It is a serious concern that in the midst of the opioid overdose epidemic there is a growing presence of kratom use in the U.S. population with a largely unregulated status.
在美国, kratom(一种植物)的使用越来越普遍,其法律地位在各州之间差异很大。有多份关于与kratom使用相关的不良事件报告,范围从肝损伤、癫痫发作、精神障碍,甚至罕见的死亡。
本研究调查了加利福尼亚州克恩县2020年的验尸官尸检报告,其中包括血液毒理学报告中关于物质的定性数据。在报告的214例与阿片类药物相关的意外过量用药案例中,有4名受试者(1.9%)在尸检报告中有米托蒽醌(kratom)暴露,并被纳入研究。我们报告了相关尸检报告中的可用人口统计学信息和合并物质发现。
所有4名有米托蒽醌(kratom)毒理学检测的个体在尸检报告中均有意外阿片类药物过量死亡记录。每个受试者至少对另一种物质的毒理学检测呈阳性。3例(75%)病例中发现了芬太尼,怀疑是这些病例中与阿片类药物相关死亡的主要原因。然而,有一例死亡病例没有芬太尼,但对苯二氮卓类、大麻和其他精神药物检测呈阳性。
这份简短报告的结果提供了关于米托蒽醌(kratom)在调节阿片类药物相关死亡风险中可能发挥的作用的见解。kratom与芬太尼等阿片类药物联合使用似乎最有可能增加致命过量用药的风险,但与苯二氮卓类和精神药物等其他药物联合使用时也可能发生。在美国阿片类药物过量流行的情况下,kratom在美国人群中的使用越来越多,且基本处于未受监管的状态,这是一个严重的问题。